Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma.

Cancer Manag Res · 2020 · PMC7733895 · PMID 33328763

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

20 A platinum-based regimen was observed with a clear trend for longer survival time than irinotecan or nal-IRI-based regimen after nab-P/G. 21 Clinical trials are always preferred for all patients with disease progression.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.